ReviewEffects of acetylcholinesterase inhibitors and memantine on resting-state electroencephalographic rhythms in Alzheimer’s disease patients
Highlights
► Symptomatic treatment options for Alzheimer’s disease (AD) are currently limited to two therapeutic classes namely, acetylcholinesterase inhibitors (AChEIs) and memantine. ► The present review clarifies the effects of AChEIs and memantine on resting-state electroencephalographic (EEG) rhythms and cognitive function in AD patients to identify EEG markers useful for drug development. ► Based on the field literature, the patient’s EEG rhythms most reactive to AChEIs are those at delta (0–3 Hz), theta (4–7 Hz) and alpha (8–12 Hz); the effects of memantine generate a reduction of pathological theta rhythms.
Section snippets
Towards the discovery of new markers and drugs for Alzheimer’s disease: the PharmaCog project
Alzheimer’s disease (AD) is the most prevalent form of dementia seen in the elderly population, and is characterised by memory loss and cognitive and other behavioural abnormalities. AD is related to neurodegeneration within the basal forebrain, parietal, prefrontal, entorhinal cortices, amygdala and hippocampus. It is characterised by an impairment of the cholinergic neurotransmission associated with a pathological production of beta amyloid (Abeta) and phosphorylated tau (Daulatzai, 2010,
Assessment of the cognitive and functional status in AD patients
The quantitative evaluation of the cognitive and functional deficits in AD patients (i.e., basic and instrumental activities of daily living, hobbies, professional duties and so on) play a key role in the diagnosis or therapy monitoring in clinical trials and are a crucial reference for the evaluation of surrogate instrumental markers to be used in these trials. As far as the assessment of the cognitive deficits is concerned, neuropsychological studies have shown that quantitative and
Standard symptomatic drugs for AD
There have been numerous preclinical and clinical studies published that report positive cognitive symptomatic effects in small-scale clinical studies in AD patients. However, these have failed to translate into significant efficacy in later stage clinical development. Despite decades of research, only two classes of pharmacological agents are currently approved for AD: the AChEIs (approved for all stages of the disease) and the NMDA receptor antagonist, memantine (approved for the later
Electroencephalographic techniques for research on AD
EEG measures brain electrical activity recorded from electrodes placed on the surface of the head. Spontaneous on-going scalp EEG rhythms reflect synchronous extracellular ion flow due to excitatory and inhibitory postsynaptic potentials in large populations of cortical pyramidal neurons (Nunez, 2000). It is also commonly accepted that scalp EEG voltages mainly correspond to the local field potentials generated in superficial cortical layers; conversely, potentials deriving from deeper cortical
Acetylcholine effects on EEG rhythms: cellular mechanisms
Cellular mechanisms at the basis of Ach effects on EEG rhythms can be summarised as follows. During slow, synchronised EEG rhythms, cortical pyramidal cells displayed low-frequency intracellular membrane oscillations and pronounced, longlasting inhibitory after-hyperpolarisations following spike discharge (Buzsáki and Gage, 1989, Metherate et al., 1992). Extracellular currents associated with these slow, synchronised membrane electrophysiological events are believed to summate in the
Pharmacological modulation of resting-state EEG rhythms in human subjects: the effects of AChEIs and memantine
Experiments on the effects of donepezil and memantine on EEG markers in humans have gained great interest owing to biochemical and pharmacological evidence of the crucial role of ACh in cognitive functions. As such, other therapeutic approaches aimed at boosting the cholinergic system are tested in clinical trials. AChEIs sustain the availability of the natural transmitter by limiting its removal from the synapse. Other approaches include administering exogenous agonists that may substitute for
Conclusions
AChEIs (especially donepezil) are the most important symptomatic treatments for mild-to-severe AD patients, while the NMDA-receptor antagonist memantine is licensed for the administration to moderate-to-severe AD patients. Here, the literature on the effects of these compounds on the resting-state eyes-closed EEG rhythms recorded in AD patients is reviewed as a knowledge platform for the identification of spectral EEG markers to be used for the development of innovative translational models for
Acknowledgements
The activity leading to the present review has received funding from the European Community’s Seventh Framework Programme (FP7/2007-2013) for the Innovative Medicine Initiative under Grant Agreement No. 115009 (Prediction of cognitive properties of new drug candidates for neurodegenerative diseases in early clinical development, PharmaCog). For further information on the PharmaCog project, please refer to http://www.pharmacog.org. We thank the staff of University of Foggia for their help in the
References (180)
- et al.
The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease
Alzheimers Dement
(2011) - et al.
Discrimination of tetrahydroaminoacridine responders by a single dose pharmaco-EEG in patients with Alzheimer’s disease
Neurosci Lett
(1991) - et al.
Hepatotoxicity of tetrahydroaminoacridine
Lancet
(1988) - et al.
Mapping distributed sources of cortical rhythms in mild Alzheimer’s disease. A multicentric EEG study
Neuroimage
(2004) - et al.
Sources of cortical rhythms change as a function of cognitive impairment in pathological aging: a multicenter study
Clin Neurophysiol
(2006) - et al.
Genotype (cystatin C) and EEG phenotype in Alzheimer disease and mild cognitive impairment: a multicentric study
Neuroimage
(2006) - et al.
Frontal white matter volume and delta EEG sources negatively correlate in awake subjects with mild cognitive impairment and Alzheimer’s disease
Clin Neurophysiol
(2006) - et al.
Donepezil effects on sources of cortical rhythms in mild Alzheimer’s disease: responders vs. non-responders
Neuroimage
(2006) - et al.
Fronto-parietal coupling of brain rhythms in mild cognitive impairment: a multicentric EEG study
Brain Res Bull
(2006) - et al.
Free copper and resting temporal EEG rhythms correlate across healthy, mild cognitive impairment, and Alzheimer’s disease subjects
Clin Neurophysiol
(2007)